Genomictree Inc. Cash Flow Conversion Efficiency

Latest as of December 2025: -0.028x

Genomictree Inc. cash flow conversion efficiency. Based on the latest financial reports, Genomictree Inc. (228760) has a cash flow conversion efficiency ratio of -0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.21 Billion ≈ $-2.18 Million USD) by net assets (₩115.31 Billion ≈ $78.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Genomictree Inc. (2020–2025)

Cash flow conversion efficiency of Genomictree Inc. from 2020 to 2025. This chart illustrates how Genomictree Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Genomictree Inc. for real-time trading data and today's change.

Genomictree Inc. Cash Flow Conversion Ratio Explained

Genomictree Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Genomictree Inc. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genomictree Inc. ranked by their cash flow conversion efficiency. Also see Genomictree Inc. market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Allpark Empreendimentos Participações e Serviços S.A SA:ALPK3	1.176x
Evolution Petroleum Corporation Inc NYSE MKT:EPM	0.080x
Lihtai Construction Enterprise Co Ltd TWO:5520	0.054x
Whitestone Group BR:ROCK	N/A
HMA AGRO INDUSTRIES ORD (BSE) NSE:HMAAGRO	0.033x
Phoenix Materials Co. Ltd KQ:050090	-0.010x
Elanor Commercial Property Fund AU:ECF	0.066x
Camlin Fine Sciences Limited NSE:CAMLINFINE	0.078x

Annual Cash Flow Conversion Efficiency for Genomictree Inc. (2020–2025)

The table below shows the annual cash flow conversion efficiency of Genomictree Inc. from 2020 to 2025. Review Genomictree Inc. free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩115.31 Billion ≈ $78.14 Million	₩-10.19 Billion ≈ $-6.91 Million	-0.088x	+19.40%
2024-12-31	₩124.32 Billion ≈ $84.25 Million	₩-13.63 Billion ≈ $-9.24 Million	-0.110x	-26.02%
2023-12-31	₩125.03 Billion ≈ $84.73 Million	₩-10.88 Billion ≈ $-7.37 Million	-0.087x	-317.38%
2022-12-31	₩107.05 Billion ≈ $72.55 Million	₩4.29 Billion ≈ $2.90 Million	0.040x	+160.38%
2021-12-31	₩115.10 Billion ≈ $78.00 Million	₩-7.63 Billion ≈ $-5.17 Million	-0.066x	+38.01%
2020-12-31	₩95.26 Billion ≈ $64.55 Million	₩-10.19 Billion ≈ $-6.90 Million	-0.107x	--

About Genomictree Inc.

KQ:228760 Korea Biotechnology

Market Cap

$154.30 Million

₩227.68 Billion KRW

Market Cap Rank

#17382 Global

#704 in Korea

Share Price

₩9480.00

Change (1 day)

-0.11%

52-Week Range

₩8950.00 - ₩32000.00

All Time High

₩38550.00